NO20054018L - Intranasal formulering av rotigotin - Google Patents
Intranasal formulering av rotigotinInfo
- Publication number
- NO20054018L NO20054018L NO20054018A NO20054018A NO20054018L NO 20054018 L NO20054018 L NO 20054018L NO 20054018 A NO20054018 A NO 20054018A NO 20054018 A NO20054018 A NO 20054018A NO 20054018 L NO20054018 L NO 20054018L
- Authority
- NO
- Norway
- Prior art keywords
- rotigotine
- intranasal formulation
- intranasal
- moisturizing
- cyclodextrin
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title abstract 2
- 229960003179 rotigotine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03029680A EP1547592A1 (fr) | 2003-12-23 | 2003-12-23 | Formulation intranasale contenant |
| PCT/EP2004/014626 WO2005063236A1 (fr) | 2003-12-23 | 2004-12-22 | Formulation intranasale de rotigotine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20054018L true NO20054018L (no) | 2005-08-30 |
Family
ID=34530709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054018A NO20054018L (no) | 2003-12-23 | 2005-08-30 | Intranasal formulering av rotigotin |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7683040B2 (fr) |
| EP (2) | EP1547592A1 (fr) |
| JP (1) | JP4430067B2 (fr) |
| KR (1) | KR100718760B1 (fr) |
| CN (1) | CN100374112C (fr) |
| AT (1) | ATE326961T1 (fr) |
| AU (1) | AU2004308641B2 (fr) |
| BR (1) | BRPI0407845A (fr) |
| CA (1) | CA2516400C (fr) |
| CY (1) | CY1105131T1 (fr) |
| DE (1) | DE602004000982T2 (fr) |
| DK (1) | DK1605932T3 (fr) |
| EA (1) | EA008005B1 (fr) |
| ES (1) | ES2262122T3 (fr) |
| HR (1) | HRP20060240T3 (fr) |
| IL (1) | IL170297A (fr) |
| IS (1) | IS2310B (fr) |
| MX (1) | MXPA05008909A (fr) |
| NO (1) | NO20054018L (fr) |
| NZ (1) | NZ541875A (fr) |
| PL (1) | PL1605932T3 (fr) |
| PT (1) | PT1605932E (fr) |
| RS (1) | RS50534B (fr) |
| SI (1) | SI1605932T1 (fr) |
| UA (1) | UA79196C2 (fr) |
| WO (1) | WO2005063236A1 (fr) |
| ZA (1) | ZA200506550B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| ES2239196T3 (es) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (fr) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Formulation intranasale contenant |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (fr) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos |
| NZ584363A (en) * | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2281559A1 (fr) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Composition pharmaceutique contenante un sel de rotigotine (sel d'acid ou Na), notament pour iontophorèse |
| LT3257504T (lt) | 2009-12-22 | 2024-08-26 | UCB Biopharma SRL | Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui |
| EP2559435A1 (fr) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine pour le traitement des négligences spatiales unilatérales, accidents vasculaires cérébraux et troubles suivant un accident vasculaire |
| WO2013075823A1 (fr) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Système thérapeutique transdermique comprenant de la rotigotine et un inhibiteur de cristallisation |
| DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
| DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
| CN103768043B (zh) * | 2012-10-22 | 2015-12-09 | 苏州药明康德新药开发股份有限公司 | 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法 |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| JP6726096B2 (ja) | 2013-07-03 | 2020-07-22 | エルテーエス ローマン テラピー−システメ アーゲー | 電子部品を有する経皮治療システム |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| CA2948219C (fr) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Methode de regulation de liberation d'agent actif dans un systeme d'administration transdermique |
| CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| CN110917125B (zh) * | 2020-01-02 | 2022-08-12 | 安徽中医药大学 | 一种罗替戈汀鼻用胶束温敏凝胶的制备方法 |
| JP7606530B2 (ja) | 2020-03-24 | 2024-12-25 | シラノ セラピューティクス， インコーポレイテッド | コロナウイルス感染症による化学感覚機能障害の治療 |
| JP2025502075A (ja) * | 2022-01-06 | 2025-01-24 | シラノ セラピューティクス， インコーポレイテッド | パーキンソン病治療剤の改善された鼻投与 |
| CN120053353A (zh) * | 2024-05-31 | 2025-05-30 | 纳索菲德(上海)制药技术有限公司 | 一种巴氯芬鼻脑递释组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108991A (en) | 1975-06-19 | 1992-04-28 | Whitby Research, Inc. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4992422A (en) | 1986-01-31 | 1991-02-12 | Whitby Research, Inc. | Compositions comprising 1-substituted azacycloalkanes |
| US5218113A (en) | 1986-01-31 | 1993-06-08 | Whitby Research, Inc. | N-substituted thiolactams |
| US4886545A (en) | 1986-01-31 | 1989-12-12 | Nelson Research & Development Company | Compositions comprising 1-substituted azacycloalkanes and their uses |
| US4755535A (en) | 1986-04-23 | 1988-07-05 | Nelson Research & Development Co. | Compositions comprising 1-substituted azacycloalkenes |
| US5073544A (en) | 1986-08-15 | 1991-12-17 | Whitby, Inc. | Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes |
| US4902676A (en) | 1986-09-29 | 1990-02-20 | Nelson Research & Development Co. | Compositions comprising N,N-dialkylalkanamides |
| DE3868866D1 (de) | 1987-11-20 | 1992-04-09 | Erba Carlo Spa | Ergolinderivate mit antiparkinsonwirkung. |
| US5472946A (en) | 1988-04-08 | 1995-12-05 | Peck; James V. | Transdermal penetration enhancers |
| US5073844A (en) * | 1991-01-11 | 1991-12-17 | The Annlouise Partnership | Lighted baggage piece |
| US6086905A (en) | 1991-03-21 | 2000-07-11 | Peck; James V. | Topical compositions useful as skin penetration barriers |
| US5308625A (en) | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
| US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| ATE290864T1 (de) | 1993-03-26 | 2005-04-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin |
| GB9324018D0 (en) | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
| US5771890A (en) | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
| DE69519023T2 (de) | 1994-06-24 | 2001-06-13 | Cygnus, Inc. | Einrichtung zur iontophoretischen probennahme |
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| EP1256339B1 (fr) | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Système thérapeutique transdermique pour l'obtention de taux plasmatiques élevés de rotigotine dans le traitement de morbus Parkinson |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| HU227543B1 (en) | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| US20040034083A1 (en) | 2002-04-18 | 2004-02-19 | Stephenson Diane T. | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
| JP4288263B2 (ja) | 2002-10-25 | 2009-07-01 | コレジウム ファーマシューティカル， インク． | ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法 |
| US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
| DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (fr) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Formulation intranasale contenant |
| CA2554616A1 (fr) | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique contenant un inhibiteur de la recapture de neurotransmetteurs monoamine et un agoniste de la dopamine |
| EP1778685B1 (fr) | 2004-08-02 | 2008-03-26 | Schwarz Pharma Ag | Carboxamides d'indolizine et leurs aza- et diaza-derives |
| DE102004054634A1 (de) | 2004-11-12 | 2006-05-18 | Schwarz Pharma Ag | Azaindolcarboxamide |
-
2003
- 2003-12-23 EP EP03029680A patent/EP1547592A1/fr not_active Withdrawn
-
2004
- 2004-12-22 WO PCT/EP2004/014626 patent/WO2005063236A1/fr not_active Ceased
- 2004-12-22 AU AU2004308641A patent/AU2004308641B2/en not_active Ceased
- 2004-12-22 BR BRPI0407845-4A patent/BRPI0407845A/pt not_active IP Right Cessation
- 2004-12-22 CA CA002516400A patent/CA2516400C/fr not_active Expired - Fee Related
- 2004-12-22 MX MXPA05008909A patent/MXPA05008909A/es active IP Right Grant
- 2004-12-22 UA UAA200508587A patent/UA79196C2/uk unknown
- 2004-12-22 KR KR1020057017173A patent/KR100718760B1/ko not_active Expired - Fee Related
- 2004-12-22 HR HR20060240T patent/HRP20060240T3/xx unknown
- 2004-12-22 AT AT04804221T patent/ATE326961T1/de active
- 2004-12-22 DK DK04804221T patent/DK1605932T3/da active
- 2004-12-22 CN CNB2004800109827A patent/CN100374112C/zh not_active Expired - Fee Related
- 2004-12-22 PL PL04804221T patent/PL1605932T3/pl unknown
- 2004-12-22 EP EP04804221A patent/EP1605932B1/fr not_active Expired - Lifetime
- 2004-12-22 NZ NZ541875A patent/NZ541875A/en unknown
- 2004-12-22 DE DE602004000982T patent/DE602004000982T2/de not_active Expired - Lifetime
- 2004-12-22 JP JP2006508291A patent/JP4430067B2/ja not_active Expired - Fee Related
- 2004-12-22 SI SI200430027T patent/SI1605932T1/sl unknown
- 2004-12-22 PT PT04804221T patent/PT1605932E/pt unknown
- 2004-12-22 EA EA200501159A patent/EA008005B1/ru not_active IP Right Cessation
- 2004-12-22 US US10/545,530 patent/US7683040B2/en not_active Expired - Fee Related
- 2004-12-22 ES ES04804221T patent/ES2262122T3/es not_active Expired - Lifetime
- 2004-12-22 RS YUP-2006/0653A patent/RS50534B/sr unknown
-
2005
- 2005-08-16 ZA ZA200506550A patent/ZA200506550B/en unknown
- 2005-08-16 IL IL170297A patent/IL170297A/en not_active IP Right Cessation
- 2005-08-30 NO NO20054018A patent/NO20054018L/no not_active Application Discontinuation
-
2006
- 2006-05-26 IS IS8487A patent/IS2310B/is unknown
- 2006-08-09 CY CY20061101113T patent/CY1105131T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054018L (no) | Intranasal formulering av rotigotin | |
| NO20061840L (no) | Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme | |
| NO20080164L (no) | N-(pyridin-2-yl)-sulfonamidderivater | |
| NO20012921L (no) | Fenylglycin-derivater | |
| TR200302105T4 (tr) | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. | |
| DK1178958T3 (da) | N-cyanomethylamider som proteaseinhibitorer | |
| NO20042161L (no) | Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1 | |
| NO20045281L (no) | Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer | |
| BR0210139A (pt) | Composições farmacêuticas | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| NO20040356L (no) | Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling. | |
| BR0209020A (pt) | Composição farmacêutica de polialilamina | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| NO20062051L (no) | Farmasoytisk virkestoffinneholdende formulering med belegg | |
| PT1556371E (pt) | Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes. | |
| ATE417617T1 (de) | Mittel zur steurung der expression von il-12 | |
| ATE357212T1 (de) | Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin | |
| NO20064521L (no) | Framgangsmate og blanding for behandling av rhinitt | |
| BRPI0411623A (pt) | forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo | |
| NO20001781L (no) | 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse | |
| AR031649A1 (es) | Composicion farmaceutica de dronedarona para administracion parenteral | |
| NO20061702L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist | |
| HUP0202324A2 (hu) | Prukaloprid orális oldat | |
| EP1362590A8 (fr) | Utilisation de cilobradine et leurs sels pharmaceutiquement accceptables pour le traitement ou la prévention de l'insuffisance cardiaque | |
| DK1411956T3 (da) | Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |